Clinical Pharmacology Clinical Trial
Official title:
Bioequivalence Study of BAY 77-1931 Orally Disintegrating Tablet - Randomized, Open-label, Two-way Crossover Study to Establish the Bioequivalence Between BAY 77-1931 Orally Disintegrating Tablet 500 mg and Fosrenol Chewable Tablet 500 mg Administered in Japanese Healthy Male Adult Subjects
The primary objective of this study was to establish the bioequivalence of two different tablet formulations containing BAY77-1931. The secondary objectives of this study were to assess the safety and tolerability, as well as to Investigate the plasma lanthanum concentration after BAY 77-1931 ODT 500 mg administration.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02629562 -
Pharmacokinetic and Pharmacodynamics of B12019 and Neulasta® in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT02286518 -
TAK-114 Single- and Multiple-Dose Phase 1 Study
|
Phase 1 | |
| Completed |
NCT01473108 -
Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862
|
Phase 1 | |
| Completed |
NCT03424135 -
A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects Under Fed Conditions
|
Phase 1 | |
| Completed |
NCT05437094 -
Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740
|
Phase 1 | |
| Completed |
NCT02276274 -
Effect of Food on the Pharmacokinetics of Single Oral Dose Administration of a Fixed-Dose Combination of SYR-322 and Metformin Hydrochloride in Healthy Adult Male Subjects
|
Phase 3 | |
| Completed |
NCT04511611 -
Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 10 mg in Japanese Healthy Male Adult Subjects
|
Phase 1 | |
| Completed |
NCT04511637 -
Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects
|
Phase 1 | |
| Completed |
NCT02113020 -
A Phase I Clinical Pharmacology Study of TAK-233 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04364464 -
Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight
|
Phase 1 | |
| Completed |
NCT06126861 -
The Mass Balance Study of LP-168 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT03517943 -
A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufactuers Under Fed Conditions in Healthy Adult Subjects
|
Phase 1 | |
| Completed |
NCT03136666 -
Single Dose Escalation Study to Investigate the Pharmacokinetics as Well as Safety and Tolerability of a Concomitant Administration of Nifedipne GITS and Candesartan Tablets Under Fasting Conditions in Healthy Male Subjects in an Open Label, Non-randomized, Sequential Design.
|
Phase 1 | |
| Completed |
NCT03517930 -
A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufacturers Under Fasted Conditions in Healthy Adult Subjects
|
Phase 1 | |
| Completed |
NCT04366622 -
Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Impaired Liver Function and Healthy Participants Matched for Age-, Gender-, and Weight
|
Phase 1 |